BCAL Diagnostics Limited (ASX:BDX)

Australia flag Australia · Delayed Price · Currency is AUD
0.115
-0.005 (-4.35%)
Mar 10, 2026, 11:12 AM AEST
16.16%
Market Cap 42.40M
Revenue (ttm) 2.54M
Net Income (ttm) -7.16M
Shares Out 368.68M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 110,000
Average Volume 109,658
Open 0.110
Previous Close 0.115
Day's Range 0.110 - 0.115
52-Week Range 0.052 - 0.155
Beta 0.70
RSI 45.57
Earnings Date n/a

About BCAL Diagnostics

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTESTplus, a first-in-class blood test designed to be used alongside standard mammogram in breast cancer screening. The company also develops BREASTEST, BCAL Diagnostics, and BCAL Dx. The company was incorporated in 2010 and is headquartered in Sydney, Australia. [Read more]

Sector Healthcare
Founded 2010
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol BDX
Full Company Profile

Financial Performance

In fiscal year 2025, BCAL Diagnostics's revenue was 2.65 million, a decrease of -13.01% compared to the previous year's 3.05 million. Losses were -7.24 million, 13.1% more than in 2024.

Financial Statements

News

There is no news available yet.